Precision Diagnostics

Uncover
all diseases

Muno reads your body's molecular signals to find what current tests miss.

PDB 7S4S · SARS-CoV-2 RBD–Antibody Complex

Be first in line for Muno Molecular™.

Current Pipeline
Muno Molecular™
Launching soon
A molecular blood test that makes the invisible visible.
Long COVID Molecular Subtyping Test
In development
First-in-class subtyping test to stratify long COVID patients by immune signature.

Your body already knows what's wrong. Your immune system, your proteins, your metabolism. Together they form a continuous map of what's happening inside you. Today, medicine reads only a fraction of that map, a few markers at a time. Millions wait years for answers that should have been theirs from the first draw of blood. We're building the technology to read the whole map. Starting where the gap is widest: complex chronic illness, where the people who need the most insight have the least access to it. Our goal is to map every signal, in every patient. Finally surfacing the patterns that have always been there.

Team

We're building an
industry best team

Jo Teichmann
Co-Founder & CEO
Serial healthtech founder
Linda Lan, PhD
Co-Founder & CSO
Immunologist at Stanford · post-acute infection
Michael Snyder, PhD
Scientific Co-Founder
Stanford Genetics Professor · multi-omics pioneer
Advisors
Michelle Roeding
Michelle Roeding
Regulatory Advisor
Ex-Natera (Senior Director of Regulatory Affairs)
Robyn Schlicher, PhD
Robyn Schlicher, PhD
Go-to-Market & Growth Advisor
Ex-Natera & Abbott

The future of diagnostics
starts here

Join the waitlist to be first in line for Muno Molecular™ — and the first to know the moment it's available.